News and Comments

XOMA: Good News for the Firm We Love and Hate But We Never Divorce

  Wednesday, December 02, 2015

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes  More...

BIOMARIN: What Happened During the FDA Committee Meeting?

  Wednesday, November 25, 2015

 More...

Biomarin: The DMD Drug and the FDA Committee Options

  Tuesday, November 24, 2015

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released to the committee by the FDA. The FDA said, “The benefit of drisapersen in exon 51 skip amenable patients is inconclusive at this time. Therefore, the benefit-risk assessments were not made.”  More...

VERTEX: Orkambi Approved In Europe. What Vertex is Doing to Further improve CF Treatments

  Friday, November 20, 2015

Europe Approves Orkambi®  More...

Ziopharm Wages Its Own War On Brain Cancer

  Thursday, November 19, 2015

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with brain glioma, we try to listen and hope for the best, rather than develop and demonstrate  skepticism. Are we not walking the road of genetic engineering, gene therapy approaches and immunotherapy? Our optimism becomes realistic, especially when a scientific rationale is explained by researchers in scientifically solid firms that are specialized in cancer treatment with novel breakthrough methods.  More...

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

Incyte is A Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015

 More...

Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...


Recent Postings


Archive


Tags

KERYX (KERX) RenenxBio (RGNX) Revlimid (lenolidamide) Multiple Myeloma Sanofi (SNY) Jazz Pharmaceuticals (JAZZ) ACADIA (ACAD) C4 Therapeutics INNOVIVA (INVA) Aimmune Therapeutics (AIMT) CEMPRA (CEMP) Mirati Therapeutics (MRTX) KITE (KITE) Alder Biopharmaceuticals (ALDR) ARCA (ABIO) GlaxoSmithKline (GSK) NANTKWEST (NK) Theravance Bio Pharma (TBPH) Sanofi-Aventis (SAN) Merck (MRK) Vertex (VRTX) Vitae Pharmaceuticals (VTAE) GUARDIAN HEALTH TOKAI (TKAOI) Abbott Laboratories (ABT) Herceptin Theravance (THRX) Human Longevity (HLI) Pluristem (PSTI) Ocular Therapeutix (OCUL) VANDA (VNDA) Tysabri Advaxis (ADXS) Human Genome Sciences (HGSI) ARGOS (ARGS) OSI (OSIP) Global Cell Therapeutics (GBT) SERES THERAPEUTICS (MCRB) Biocryst (BCRX) Endometrial Cancer Array Pharmaceuticals (ARRY) Spike Therapeutics (ONCE) Intermune (ITMN) ADVENTRIX (ANX) NOVOCURE (NVCR) Sequenom (SQNM) Genentech Sanofi (SNA) Ziofpharm (ZIOP) REGULUS (RGLS) Prosensa (RNA) Trastuzumab-DM1 BIOMARIN (BMRN) AGOS (ARGS) AERIE PHARMACEUTICALS Alnylam (ALNY) CompuGen (CGEN) Prolor Biotech (PBTH) ABBVIE (ABBV) Amgen (AMGN) Cytokinetics (CYTK) ISIS (ISIS) JUNO (JUNO) Rapamune Anadys (ANDS) CRISPR Therapeutics (CRSP) Galena (GALE) Agenus (AGEN) Bristol-Myers Squibb (BMY) IDERA (IDRA) Exelixis (EXEL) Seattle Genetics (SGEN) AstraZeneca (AZN) Adaptimmune (ADAP) Micromet (MITI) Valeant Pharmaceuticals International (VRX) Bellicum (BLCM) Elan (ELN) MODERNA Inovio (INO) Roche (RHHBY) Onyx (ONXX) Intercept (ICPT) PTC Therapeutics (PTCT) Sangamo (SGMO) Incyte (INCY) Telaprevir Xoma (XOMA) Benlysta (belimumab) NEKTAR (NKTR)) Ridaforolimus Velcade (bortezomib) Anacor (ANAC) Auspex (ASPX) Zerenex SUNESIS PHARMACEUTICALS (SNSS) Editas (EDIT) Gilead (GILD) Illumina (ILMN) Biogen Idec (BIIB) galapagos (GLPG) HALOZYME (HALO) SYNTA (SNTA) Agenus (AGEN Ariad (ARIA) Dendreon (DNDN) Intrexon (XON) Idenix (IDIX) ZALTRAP™ Roche (ROCHE) Sarepta (SRPT) ImmunoGen (IMGN) Dynavax (DVAX) Regeneron (REGN) Ionis (IONS)